The Johnson & Johnson laboratory advances the first data of its vaccine against the Coronavirus Covid-19: a single dose, immune response for months.
There is a crucial moment in the evolutionary trajectory of the global pandemic of Coronavirus Covid-19. The first vaccines have already begun to be mass produced to be applied in different sectors.
But it is also the moment in which we are seeing new projects from laboratories that previously did not show as much weight in the competition.
And it turns out that, at least in the case of Johnson & Johnson, they promise to achieve vaccines much more affective than the current ones.
A single dose vaccine
As reported by friends of CNN, The North American company Johnson & Johnson has published the first results of phase 2 of its experimental vaccine against Coronavirus Covi-19 with encouraging results.
In this stage they participated 800 volunteers of all age groups who received this prototype antidote that would require a single injection and not two, unlike virtually all existing vaccines.
The age group between 18 and 55 years of age showed a stable and constant development of antibodies for at least 71 days and more than 90% of the participants showed a favorable reaction.
An active immune response lasted for about a full month among virtually all volunteers. The single injection vaccine generates more neutralizing antibodies than a single dose of its competition that requires two injection phases.
There are side effects such as fever, fatigue, headache, and muscle pain in the puncture area. But so far it seems that nothing unusual has been presented.
Although the project is just closing its second phase. So even in the best-case scenario, the Johnson & Johnson vaccine wouldn’t be approved until after March 2021.